市場調查報告書

腫瘤基因學的全球市場:分析與預測 (各產品、各技術、各用途、各終端用戶、癌症的各類型、各地區 (共14個國家)),產業分析,競爭環境 (2019∼2028年)

Global Tumor Genomics Market: Focus on Products, Techniques, Applications, End User, Cancer Type, 14 Countries Data, Industry Insights and Competitive Landscape - Analysis and Forecast, 2019-2028

出版商 BIS Research Inc. 商品編碼 940008
出版日期 內容資訊 英文 259 Pages
商品交期: 最快1-2個工作天內
價格
腫瘤基因學的全球市場:分析與預測 (各產品、各技術、各用途、各終端用戶、癌症的各類型、各地區 (共14個國家)),產業分析,競爭環境 (2019∼2028年) Global Tumor Genomics Market: Focus on Products, Techniques, Applications, End User, Cancer Type, 14 Countries Data, Industry Insights and Competitive Landscape - Analysis and Forecast, 2019-2028
出版日期: 2020年05月31日內容資訊: 英文 259 Pages
簡介

全球腫瘤基因學市場,至2028年預計達到162億8720萬美元的規模。

本報告提供全球腫瘤基因學市場相關分析,疾病的概要和市場基本結構,主要的推動及阻礙市場要素,整體市場規模趨勢預測 (今後10年份),各產品、各技術、各用途、各終端用戶、癌症的各類型及各地區/主要國家詳細趨勢,市場競爭狀態,主要企業的簡介等資訊彙整,為您概述為以下內容。

摘要整理

第1章 產品定義

第2章 分析範圍

第3章 分析方法

第4章 全球腫瘤基因學市場

  • 市場概要
  • 腫瘤基因學:概要
  • 腫瘤基因技術的演進
  • 全球市場方案主要的技術趨勢

第5章 市場動態

  • 簡介
  • 影響力分析
  • 推動市場要素
  • 阻礙市場要素
  • 市場機會

第6章 產業考察

  • 法規必要條件:各國

第7章 競爭環境

  • 主要趨勢與策略
    • 夥伴關係、聯盟
    • 新產品的銷售
    • 企業合併、收購 (M&A) 活動
    • 事業擴張
    • 其他
  • 市場佔有率分析
    • 市場佔有率分析(各企業)
  • 成長佔有率分析
    • 成長佔有率矩陣(各企業)

第8章 全球腫瘤基因學市場(各產品)

  • 化驗、套件
  • 分析設備

第9章 全球腫瘤基因學市場(各技術)

  • 下一代序列(NGS)
  • 聚合酵素鏈鎖反應(PCR)
  • 微陣列
  • In-Situ雜合反應(ISH)
  • 免疫組織化學(IHC)
  • 其他技術(質譜分析,流式細胞技術)

第10章 全球腫瘤基因市場(各用途)

  • 診斷和監測
  • 藥物研發與開發
  • 生物標記的發現

第11章 全球腫瘤基因學市場(各終端用戶)

  • 教育、研究機關
  • 醫院,門診病人診療所
  • 臨床/診斷檢驗室
  • 生物科技、製藥公司

第12章 全球腫瘤基因學市場(癌症的各類型)

  • 白血病
  • 乳癌
  • 黑色素瘤
  • 大腸癌症
  • 肺癌症
  • 前列腺癌症
  • 頭頸椎癌症
  • 其他(卵巢,胰臟,精巢)

第13章 全球腫瘤基因市場(各地區)

  • 北美
    • 北美的腫瘤基因學市場(各國)
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 其他
  • 亞太地區(APAC)
    • 中國
    • 日本
    • 澳洲
    • 印度
    • 其他
  • 其他的國家 (RoW)
    • 南美
    • 中東、非洲

第14章 企業簡介

  • Abbott Laboratories
    • 企業概要
    • 全球腫瘤基因學市場上作用
    • 財務分析
    • 財務狀況相關考察
    • SWOT分析
  • Agilent Technologies,Inc.
  • Bio-Rad Laboratories,Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Fluidigm Corporation
  • General Electric Company
  • Illumina, Inc.
  • Merck KGaA
  • Myriad Genetics,Inc.
  • Pacific Biosciences of California,Inc.
  • PerkinElmer
  • QIAGEN
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
目錄
Product Code: BH205A

Global Tumor Genomics Market to Reach $16,287.2 Million by 2028

Market Report Coverage - Tumor Genomics

Market Segmentation

By Product: Assays and Kits, and Instruments

By Technique: Next Generation Sequencing Technique (NGS), Polymerase Chain Reaction (PCR), Microarray, In-Situ Hybridization (ISH), Immunohistochemistry (ICH), Others (Mass Spectrometry and Flow Cytometry)

By Application: Diagnostics and Monitoring, Drug Discovery and Development, and Biomarker Discovery

By End User: Academics and Research Organizations, Hospitals and Ambulatory Clinics, Clinical and Diagnostic Laboratories, and Biotechnology and Pharmaceutical Company

By Cancer Type: Leukemia, Breast Cancer, Melanoma, Colon Cancer, Lung Cancer, Prostate Cancer, Head and Neck Cancer, and Others (Ovarian, Pancreatic, and Testicular)

Regional Segmentation

North America - U.S., Canada

Europe - Germany, U.K., France, Italy, Spain, Netherlands, Rest-of-Europe

Asia-Pacific - Japan, China, Australia, India, Rest-of-Asia-Pacific

  • Rest-of-the-World - Latin America and Middle East & Africa

Growth Drivers

Rising Government Initiatives and Projects

Increasing Incidence of Cancer

Increasing Number of Product Approvals and Launches

Ever Expanding Application Areas for Genomics

Increasing Use of Biomarkers in Cancer Profiling

Market Challenges

High Cost of Genomic Equipment

Lack of Unified Framework for Data Integration

Market Opportunities

Growing Prominence for Precision Medicine

Increasing Demand for Point-of-Care Diagnostics

Key Companies Profiled

Thermo Fisher Scientific Inc., Illumina, Inc., QIAGEN, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Merck KGaA, Pacific Biosciences of California, Inc., Myriad Genetics, Inc., and PerkinElmer.

Key Questions Answered:

  • What is tumor genomics? How the different tumor genomic techniques have evolved over the years?
  • What are the major market drivers, challenges, and opportunities in the global tumor genomics market?
  • What was the global tumor genomics market size in terms of revenue in 2019? How is the market expected to evolve in the upcoming years? What is the market size expected to be in 2028?
  • How is each segment of the global tumor genomics market expected to grow during the forecast period between 2020 to 2028 and what is the revenue expected to be generated by each of the segments by the end of 2028?
  • What are the developmental strategies implemented by the key players to sustain in the competitive market?
  • What is the growth potential of the tumor genomics market in each region, namely, North America, Europe, Asia-Pacific, and the Rest-of-the-World?
  • Which product among the two (assays and kits & instrument) are offered by key players such as Thermo Fisher Scientific, Illumina Inc., Qiagen N.V., and F. Hoffmann-La Roche Ltd.?
  • Which technique is leading the market in 2018 and expected to dominate the market in 2028 and why?
  • Which application and end user type are leading the market in 2019 and are expected to dominate the market in 2028 and why?
  • Which region dominated the global tumor genomics market in 2019 and what are the expected trends from each of the regions in the forecast period 2020-2028?

Market Overview

In order to meet the growing product demand and need, companies are investing in the assays, kits, and instruments used in tumor genomics. Nowadays, large number of kits and reagents are used to test the profiling of mutated genes. For instance, companies such as Thermo Fisher Scientific, Illumina, Inc., and QIAGEN N.V. have focused on the development of variety of kits for the detection of rare genetic diseases due to cost-effectiveness of the kit as compared to instrument and software, which in turn is causing widespread utilization of kits globally.

The market is also witnessing the launches of various products by receiving FDA approvals such as assay for the study of genes and molecular characterization of DNA. For instance, on, January 16, 2019, QIAGEN received approval from Japanese Pharmaceuticals and Medical Device Agency (PMDA) on therascreen EGFR RGQ PCR Kit which is used as a companion diagnostic for lung cancer patients on treatment with Dacomitinib.

Similarly, several manufacturers are also launching innovative products to expand their offerings in the market. For instance, on November 6, 2019, Thermo Fisher Scientific launched Ion Torrent Genexus System, which is a fully integrated next generation sequencing platform used for profiling of genomes.

The market is favored by multiple factors, which include rising government initiatives, increasing incidence of cancer, therefore increasing the utilization of sequencing to identify the mutant DNA segments, increasing number of product approvals and launches pertaining to genomics market. Moreover, increasing use of biomarkers in cancer profiling is also one of the key driving factors for tumor genomics market.

Government funding is also one of the major growth factors for tumor genomics market, because increasing funding by the government help the research institutes to develop sequencing systems useful for the diagnosis of genetic diseases. Increasing funding shall lead to liquidity of the genomics market and thus companies shall develop various sequencing systems to identify the mutation in the segments of DNA. All these factors are thus expected to contribute to the market growth during the forecast period.

Within the research report, the market is segmented on the basis of product type, techniques, application, end user, cancer type, and region, which highlight value propositions and business models useful for industry leaders and stakeholders. The research also comprises country-level analysis, go-to-market strategies of leading players, future opportunities, among others, to detail the scope and provide a 360-coverage of the domain.

Competitive Landscape

Major players including QIAGEN N.V., Illumina, Inc., Abbott Laboratories, F. Hoffmann-La Roche Ltd. Thermo Fisher Scientific, and BGI, among others, led the number of synergistic developments (partnerships and alliances) witnessed by the market. On the basis of region, North America is expected to retain a leading position throughout the forecast period 2019-2029, followed by Europe. This is a result of the presence of leading industry players in these regions, and a higher adoption rate of sequencing system to detect the mutation in genes and DNA segments. Moreover, growing research in the field of sequencing technologies including next-generation sequencing technologies (NGS) is one of the drivers that promote the growth of the tumor genomics market.

Executive Summary

1 Product Definition

  • 1.1 Inclusion and Exclusion

2 Research Scope

  • 2.1 Scope of the Study
  • 2.2 Key Questions Answered in the Report

3 Research Methodology

  • 3.1 Global Tumor Genomics: Research Methodology
  • 3.2 Primary Data Sources
  • 3.3 Secondary data sources
  • 3.4 Data Triangulation
  • 3.5 Segmentation of the Global Tumor Genomics Market
  • 3.6 Inclusion and Exclusion
  • 3.7 Base Year and Forecast Year

4 Global Tumor Genomics Market

  • 4.1 Market Overview
  • 4.2 Introduction to Tumor Genomics
  • 4.3 Evolution of Tumor Genomic Techniques
  • 4.4 Global Market Scenario and Key Technology Trends

5 Market Dynamics

  • 5.1 Introduction
  • 5.2 Impact Analysis
  • 5.3 Market Drivers
    • 5.3.1 Rising Government Initiatives and Projects
    • 5.3.2 Increasing Incidence of Cancer
    • 5.3.3 Increasing Number of Product Approval and Launches
    • 5.3.4 Ever Expanding Application Areas for Genomics
    • 5.3.5 Increasing Use of Biomarkers in Cancer Profiling
  • 5.4 Market Restraints
    • 5.4.1 High Cost of Genomic Equipment
    • 5.4.2 Lack of Unified Framework for Data Integration
  • 5.5 Market Opportunities
    • 5.5.1 Growing Prominence for Precision Medicine
    • 5.5.2 Increasing Demand for Point-of-Care Diagnostics

6 Industry Insights

  • 6.1 Regulatory Requirements
    • 6.1.1 Regulatory Framework in the U.S.
      • 6.1.1.1 Guidelines Published in FY2018
      • 6.1.1.2 Guidelines Published in FY2016
    • 6.1.2 Europe
    • 6.1.3 Japan
  • 6.2 Patent Analysis

7 Competitive Landscape

  • 7.1 Key Developments and Strategies
    • 7.1.1 Partnerships and Alliances
    • 7.1.2 New Product Launches
    • 7.1.3 Mergers and Acquisition Activities
    • 7.1.4 Business Expansions
    • 7.1.5 Others
  • 7.2 Market Share Analysis
    • 7.2.1 Market Share Analysis (by Company)
  • 7.3 Growth Share Analysis
    • 7.3.1 Growth Share Matrix (by Company)

8 Global Tumor Genomics Market (by Product)

  • 8.1 Assays and Kits
  • 8.2 Instrument

9 Global Tumor Genomics Market (by Technique)

  • 9.1 Next Generation Sequencing (NGS)
  • 9.2 Polymerase Chain Reaction (PCR)
  • 9.3 Microarray
  • 9.4 In-Situ Hybridization (ISH)
  • 9.5 Immunohistochemistry (IHC)
  • 9.6 Other Technologies (Mass Spectrometry and Flow Cytometry)

10 Global Tumor Genomics Market (by Application)

  • 10.1 Diagnostics and Monitoring
  • 10.2 Drug Discovery and Development
  • 10.3 Biomarker Discovery

11 Global Tumor Genomics Market (by End User)

  • 11.1 Academics and Research Organizations
  • 11.2 Hospitals and Ambulatory Clinics
  • 11.3 Clinical and Diagnostic Laboratories
  • 11.4 Biotechnology and Pharmaceutical Companies

12 Global Tumor Genomics Market (by Cancer Type)

  • 12.1 Leukemia
  • 12.2 Breast Cancer
  • 12.3 Melanoma
  • 12.4 Colon Cancer
  • 12.5 Lung Cancer
  • 12.6 Prostate Cancer
  • 12.7 Head and Neck Cancer
  • 12.8 Others (Ovarian, Pancreatic, and Testicular)

13 Global Tumor Genomics Market (By Region)

  • 13.1 North America
    • 13.1.1 North America Tumor Genomics Market (by Country)
    • 13.1.2 U.S.
    • 13.1.3 Canada
  • 13.2 Europe
    • 13.2.1 Europe Tumor Genomics Market (by Country)
    • 13.2.2 Germany
    • 13.2.3 U.K.
    • 13.2.4 France
    • 13.2.5 Italy
    • 13.2.6 Spain
    • 13.2.7 Netherlands
    • 13.2.8 Rest-of-Europe
  • 13.3 Asia-Pacific (APAC)
    • 13.3.1 Asia-Pacific Tumor Genomics Market (by Country)
    • 13.3.2 China
    • 13.3.3 Japan
    • 13.3.4 Australia
    • 13.3.5 India
    • 13.3.6 Rest-of-Asia-Pacific
  • 13.4 Rest-of-the-World
    • 13.4.1 Rest-of-the-World Tumor Genomics Market (by Country)
    • 13.4.2 Latin America
    • 13.4.3 Middle East & Africa

14 Company Profiles

  • 14.1 Abbott Laboratories
    • 14.1.1 Company Overview
    • 14.1.2 Role of Abbott Laboratories in the Global Tumor Genomics Market
    • 14.1.3 Financials
    • 14.1.4 Key Insights About Financial Health of the Company
    • 14.1.5 SWOT Analysis
  • 14.2 Agilent Technologies, Inc.
    • 14.2.1 Company Overview
    • 14.2.2 Role of Agilent Technologies, Inc. in the Global Tumor Genomics Market
    • 14.2.3 Financials
    • 14.2.4 Key Insights About Financial Health of the Company
    • 14.2.5 SWOT Analysis
  • 14.3 Bio-Rad Laboratories, Inc.
    • 14.3.1 Company Overview
    • 14.3.2 Role of Bio-Rad Laboratories, Inc. in the Global Tumor Genomics Market
    • 14.3.3 Financials
    • 14.3.4 Key Insights About Financial Health of the Company
    • 14.3.5 SWOT Analysis
  • 14.4 Danaher Corporation
    • 14.4.1 Company Overview
    • 14.4.2 Role of Danaher Corporation in the Global Tumor Genomics Market
    • 14.4.3 Financials
    • 14.4.4 Key Insights About Financial Health of the Company
    • 14.4.5 SWOT Analysis
  • 14.5 F. Hoffmann-La Roche Ltd
    • 14.5.1 Company Overview
    • 14.5.2 Role of F. Hoffmann-La Roche Ltd in the Global Tumor Genomics Market
    • 14.5.3 Financials
    • 14.5.4 Key Insights About Financial Health of the Company
    • 14.5.5 SWOT Analysis
  • 14.6 Fluidigm Corporation
    • 14.6.1 Company Overview
    • 14.6.2 Role of Fluidigm Corporation in the Global Tumor Genomics Market
    • 14.6.3 Financials
    • 14.6.4 Key Insights About Financial Health of the Company
    • 14.6.5 SWOT Analysis
  • 14.7 General Electric Company
    • 14.7.1 Company Overview
    • 14.7.2 Role of General Electric Company in the Global Tumor Genomics Market
    • 14.7.3 Financials
    • 14.7.4 Key Insights About Financial Health of the Company
    • 14.7.5 SWOT Analysis
  • 14.8 Illumina, Inc.
    • 14.8.1 Company Overview
    • 14.8.2 Role of Illumina, Inc. in the Global Tumor Genomic Market
    • 14.8.3 Financials
    • 14.8.4 Key Insights About Financial Health of the Company
    • 14.8.5 SWOT Analysis
  • 14.9 Merck KGaA
    • 14.9.1 Company Overview
    • 14.9.2 Role of Merck KGaA in the Global Tumor Genomics Market
    • 14.9.3 Financials
    • 14.9.4 Key Insights About Financial Health of the Company
    • 14.9.5 SWOT Analysis
  • 14.10 Myriad Genetics, Inc.
    • 14.10.1 Company Overview
    • 14.10.2 Role of Myriad Genetics, Inc. in the Global Tumor Genomics Market
    • 14.10.3 Financials
    • 14.10.4 Key Insights About Financial Health of the Company
    • 14.10.5 SWOT Analysis
  • 14.11 Pacific Biosciences of California, Inc.
    • 14.11.1 Company Overview
    • 14.11.2 Role of Pacific Biosciences of California, Inc. in the Global Tumor Genomics Market
    • 14.11.3 Financials
    • 14.11.4 Key Insights About Financial Health of the Company
    • 14.11.5 SWOT Analysis
  • 14.12 PerkinElmer
    • 14.12.1 Company Overview
    • 14.12.2 Role of PerkinElmer in the Global Tumor Genomics Market
    • 14.12.3 Financials
    • 14.12.4 Key Insights about Financial Health of the Company
    • 14.12.5 SWOT Analysis
  • 14.13 QIAGEN
    • 14.13.1 Company Overview
    • 14.13.2 Role of QIAGEN in the Global Tumor Genomics Market
    • 14.13.3 Financials
    • 14.13.4 Key Insights about Financial Health of the Company
    • 14.13.5 SWOT Analysis
  • 14.14 Siemens Healthineers AG
    • 14.14.1 Company Overview
    • 14.14.2 Role of Siemens Healthineers AG in the Global Tumor Genomics Market
    • 14.14.3 Financials
    • 14.14.4 Key Insights about Financial Health of the Company
    • 14.14.5 SWOT Analysis
  • 14.15 Thermo Fisher Scientific Inc.
    • 14.15.1 Company Overview
    • 14.15.2 Role of Thermo Fisher Scientific Inc. in the Global Tumor Genomics Market
    • 14.15.3 Financials
    • 14.15.4 Key Insights on the Financial Health of the Company
    • 14.15.5 SWOT Analysis

List of Tables

  • Table 1: Key Product Launches Between May 2017-February 2020
  • Table 5.1: Impact Analysis of Market Drivers
  • Table 5.2: Impact analysis of Market Restraints
  • Table 5.3: Number of Product Launches (2018-2020)
  • Table 5.4: Number of Product Approvals (2018 and 2019)
  • Table 6.1: List of Major Regulatory Bodies and Associations across the World
  • Table 6.2: Global Tumor Genomics Market: Patent Analysis
  • Table 8.1: Competitive Benchmarking by Product and Technique

List of Figures

  • Figure 1: Percentage of Cancer Deaths, by Type: 2007-2020
  • Figure 2: Global Tumor Genomics Market Value, 2018-2028
  • Figure 3: Drivers and Restraints of Global Tumor Genomics Market
  • Figure 4: Share of Key Developments and Strategies, January 2017-February 2020
  • Figure 5: Global Tumor Genomics Market (by Product), 2018-2028
  • Figure 6: Global Tumor Genomics Market (by Technique), 2018-2028
  • Figure 7: Global Tumor Genomics Market (by Application), 2018-2028
  • Figure 8: Global Tumor Genomics Market (by End User), 2018-2028
  • Figure 9: Global Tumor Genomics Market (by Cancer Type), 2018-2028
  • Figure 10: Global Tumor Genomics Market (by Region): 2019 and 2028
  • Figure 3.1: Global Tumor Genomics Market Research Methodology
  • Figure 3.2: Primary Research
  • Figure 3.3: Secondary Research
  • Figure 3.4: Data Triangulation
  • Figure 3.5: Top-Down Approach (Segment-Wise Analysis)
  • Figure 3.6: Bottom-up Approach (Segment-Wise Analysis)
  • Figure 3.7: Assumptions and Limitations
  • Figure 3.8: Assumptions and Limitations
  • Figure 3.9: Segmentation of the Global Tumor Genomics Market
  • Figure 4.1: Evolution of Tumor Genomic Techniques
  • Figure 4.2: Global Tumor Genomics Market Size, 2018-2028
  • Figure 5.1: Incidence of Different Cancers (2014-2017)
  • Figure 7.1: Competitive Landscape, January 2017-February 2020
  • Figure 7.2: Share of Key Developments and Strategies, January 2017-February 2020
  • Figure 7.3: Partnerships and Alliances (by Company), January 2017-February 2020
  • Figure 7.4: New Product Launches (by Company), January 2017-February 2020
  • Figure 7.5: Others (by Company), January 2017-February 2020
  • Figure 7.6: Market Share Analysis for the Global Tumor Genomics Market, by Company (2019)
  • Figure 7.7: Growth Share Matrix: Global Tumor Genomics Market (by Company), 2018-2019
  • Figure 8.1: Global Tumor Genomics Market (by Product)
  • Figure 8.2: Global Tumor Genomics Market (by Product), 2018-2028
  • Figure 8.3: Global Tumor Genomics Market for Assays and Kits, 2018-2028
  • Figure 8.4: Global Tumor Genomics Market for Instruments, 2018-2028
  • Figure 9.1: Global Tumor Genomics Market, by Techniques
  • Figure 9.2: Global Tumor Genomics Market (by Technique), 2018-2028
  • Figure 9.3: Global Tumor Genomics Market (Technique: Next-Generation Sequencing), 2018-2028
  • Figure 9.4: Global Tumor Genomics Market (Technique: Polymerase Chain Reaction), 2018-2028
  • Figure 9.5: Global Tumor Genomics Market (Technique: Microarray) , 2018-2028
  • Figure 9.6: Global Tumor Genomics Market (Technique: In-Situ Hybridization), 2018-2028
  • Figure 9.7: Global Tumor Genomics Market (Technique: Immunohistochemistry), 2018-2028
  • Figure 9.8: Global Tumor Genomics Market (Technique: Other Technologies {Mass Spectrometry and Flow Cytometry}), 2018-2028
  • Figure 10.1: Global Tumor Genomics Market, by Application
  • Figure 10.2: Global Tumor Genomics Market (by Application), 2018-2028
  • Figure 10.3: Global Tumor Genomics Market (Application: Diagnostics and Monitoring), 2018-2028
  • Figure 10.4: Global Tumor Genomics Market (Application: Drug Discovery and Development), 2018-2028
  • Figure 10.5: Global Tumor Genomics Market (Application: Biomarker Discovery), 2018-2028
  • Figure 11.1: Global Tumor Genomics Market, by End User
  • Figure 11.2: Global Tumor Genomics Market (by End User), 2018-2028
  • Figure 11.3: Global Tumor Genomics Market (End User: Academics and Research Organizations), 2018-2028
  • Figure 11.4: Global Tumor Genomics Market (End User: Hospitals and Ambulatory Clinics), 2018-2028
  • Figure 11.5: Global Tumor Genomics Market (End User: Clinical and Diagnostic Laboratories), 2018-2028
  • Figure 11.6: Global Tumor Genomics Market (End User: Biotechnology and Pharmaceutical Company), 2018-2028
  • Figure 12.1: Global Tumor Genomics Market, by Cancer Type
  • Figure 12.2: Global Tumor Genomics Market (by Cancer Type), 2018-2028
  • Figure 12.3: Global Tumor Genomics Market (Cancer Type: Leukemia), 2018-2028
  • Figure 12.4: Global Tumor Genomics Market (Cancer Type: Breast Cancer), 2018-2028
  • Figure 12.5: Global Tumor Genomics Market (Cancer Type: Melanoma), 2018-2028
  • Figure 12.6: Global Tumor Genomics Market (Cancer Type: Colon Cancer), 2018-2028
  • Figure 12.7: Global Tumor Genomics Market (Cancer Type: Lung Cancer), 2018-2028
  • Figure 12.8: Global Tumor Genomics Market (Cancer Type: Prostate Cancer), 2018-2028
  • Figure 12.9: Global Tumor Genomics Market (Cancer Type: Head and Neck Cancer), 2018-2028
  • Figure 12.10: Global Tumor Genomics Market (Cancer Type: Others {Ovarian, Pancreatic, and Testicular}), 2018-2028
  • Figure 13.1: Global Tumor Genomics Market (by Region), 2019 and 2028
  • Figure 13.2: North America Tumor Genomics Market, 2018-2028
  • Figure 13.3: North America: Market Dynamics
  • Figure 13.4: North America Tumor Genomics Market (by Country), 2019 and 2028
  • Figure 13.5: U.S. Tumor Genomics Market, 2018-2028
  • Figure 13.6: Canada: Tumor Genomics Market, 2018-2028
  • Figure 13.7: Europe: Tumor Genomics Market, 2018-2028
  • Figure 13.8: Europe: Market Dynamics
  • Figure 13.9: Europe Tumor Genomics Market (by Country), 2019 and 2028
  • Figure 13.10: Germany Tumor Genomics Market, 2018-2028
  • Figure 13.11: U.K. Tumor Genomics Market, 2018-2028
  • Figure 13.12: France Tumor Genomics Market, 2018-2028
  • Figure 13.13: Italy Tumor Genomics Market, 2018-2028
  • Figure 13.14: Spain Tumor Genomics Market, 2018-2028
  • Figure 13.15: Netherlands Tumor Genomics Market, 2018-2028
  • Figure 13.16: Rest-of-Europe Tumor Genomics Market, 2018-2028
  • Figure 13.17: Asia-Pacific: Tumor Genomics Market, 2018-2028
  • Figure 13.18: Asia-Pacific: Market Dynamics
  • Figure 13.19: Asia-PacificTumor Genomics Market (by Country), 2019 and 2028
  • Figure 13.20: China Tumor Genomics Market, 2018-2028
  • Figure 13.21: Japan Tumor Genomics Market, 2018-2028
  • Figure 13.22: Australia Tumor Genomics Market, 2018-2028
  • Figure 13.23: India Tumor Genomics Market, 2018-2028
  • Figure 13.24: Rest-of-Asia-Pacific Tumor Genomics Market, 2018-2028
  • Figure 13.25: Rest-of-the-World Tumor Genomics Market, 2018-2028
  • Figure 13.26: Rest-of-the-World (RoW): Market Dynamics
  • Figure 13.27: Rest-of-the-World Tumor Genomics Market (by Country), 2019 and 2028
  • Figure 13.28: Latin America Tumor Genomics Market, 2018-2028
  • Figure 13.29: Middle East & Africa Tumor Genomics Market, 2018-2028
  • Figure 14.1: Abbott Laboratories: Product Offerings for the Global Tumor Genomics Market
  • Figure 14.2: Abbott Laboratories: Overall Financials, 2017-2019
  • Figure 14.3: Abbott Laboratories: Revenue (by Product/Service), 2017-2019
  • Figure 14.4: Abbott Laboratories: Revenue (by Region), 2017-2019
  • Figure 14.5: Abbott Laboratories: R&D Expenditure, 2017-2019
  • Figure 14.6: Abbott Laboratories: SWOT Analysis
  • Figure 14.7: Agilent Technologies, Inc.: Product Offerings for the Global Tumor Genomics Market
  • Figure 14.8: Agilent Technologies, Inc.: Overall Financials, 2017-2019
  • Figure 14.9: Agilent Technologies, Inc.: Revenue (by Business Model), 2017-2019
  • Figure 14.10: Agilent Technologies, Inc.: Revenue (by Region), 2017-2019
  • Figure 14.11: Agilent Technologies, Inc.: R&D Expenditure, 2017-2019
  • Figure 14.12: Agilent Technologies, Inc.: SWOT Analysis
  • Figure 14.13: Bio-Rad Laboratories, Inc.: Product Offerings for the Global Tumor Genomics Market
  • Figure 14.14: Bio-Rad Laboratories, Inc.: Overall Financials, 2016-2018
  • Figure 14.15: Bio-Rad Laboratories, Inc.: Revenue (by Product/Service), 2016-2018
  • Figure 14.16: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2016-2018
  • Figure 14.17: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2016-2018
  • Figure 14.18: Bio-Rad Laboratories, Inc.: SWOT Analysis
  • Figure 14.19: Danaher Corporation Product Offerings for the Global Tumor Genomics Market
  • Figure 14.20: Danaher Corporation: Overall Financials, 2017-2019
  • Figure 14.21: Danaher Corporation: Revenue (by Product/Service), 2017-2019
  • Figure 14.22: Danaher Corporation: Revenue (by Region), 2017-2019
  • Figure 14.23: Danaher Corporation: R&D Expenditure, 2017-2019
  • Figure 14.24: Danaher Corporation: SWOT Analysis
  • Figure 14.25: F. Hoffman-La-Roche Ltd: Product Offerings for the Global Tumor Genomics Market
  • Figure 14.26: F. Hoffmann-La Roche Ltd: Overall Financials, 2017-2019
  • Figure 14.27: F. Hoffmann-La Roche Ltd: Revenue (by Product/Service), 2017-2019
  • Figure 14.28: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2017-2019
  • Figure 14.29: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2018-2018
  • Figure 14.30: F. Hoffmann-La Roche AG: SWOT Analysis
  • Figure 14.31: Fluidigm Corporation: Overall Product Portfolio
  • Figure 14.32: Fluidigm Corporation: Overall Financials, 2017-2019
  • Figure 14.33: Fluidigm Corporation: Revenue (by Business Segment), 2016-2018
  • Figure 14.34: Fluidigm Corporation: Revenue (by Region), 2016-2018
  • Figure 14.35: Fluidigm Corporation: R&D Expenditure, 2016-2018
  • Figure 14.36: Fluidigm Corporation: SWOT Analysis
  • Figure 14.37: General Electric Company: Product Offerings for the Global Tumor Genomics Market
  • Figure 14.38: General Electric Company: Overall Financials, 2017-2019
  • Figure 14.39: General Electric Company: Revenue (by Business Model), 2017-2019
  • Figure 14.40: General Electric Company: Revenue (by Region), 2017-2019
  • Figure 14.41: General Electric Company: R&D Expenditure, 2017-2019
  • Figure 14.42: General Electric Company: SWOT Analysis
  • Figure 14.43: Illumina, Inc.: Product Offerings for the Global Tumor Genomics Market
  • Figure 14.44: Illumina, Inc.: Overall Financials, 2016-2018
  • Figure 14.45: Illumina Inc.: Revenue (by Segment), 2016-2018
  • Figure 14.46: Illumina, Inc.: Revenue (by Region), 2016-2018
  • Figure 14.47: Illumina, Inc.: R&D Expenditure, 2016-2018
  • Figure 14.48: Illumina, Inc.: SWOT Analysis
  • Figure 14.49: Merck KGaA: Product Offerings for the Global Tumor Genomics Market
  • Figure 14.50: Merck KGaA: Overall Financials, 2017-2019
  • Figure 14.51: Merck KGaA: Revenue (by Product/Service), 2017-2019
  • Figure 14.52: Merck KGaA: Revenue (by Region), 2017-2019
  • Figure 14.53: Merck KGaA: R&D Expenditure, 2017-2019
  • Figure 14.54: Merck KGaA: SWOT Analysis
  • Figure 14.55: Myriad Genetics, Inc.: Product Offerings for the Global Tumor Genomics Market
  • Figure 14.56: Myriad Genetics, Inc.: Overall Financials, 2017-2019
  • Figure 14.57: Myriad Genetics, Inc.: Revenue (by Product/Service), 2017-2019
  • Figure 14.58: Myriad Genetics, Inc.: R&D Expenditure, 2017-2019
  • Figure 14.59: Myriad Genetics, Inc.: SWOT Analysis
  • Figure 14.60: Bio-Rad Laboratories, Inc.: Overall Product Portfolio
  • Figure 14.61: Pacific Biosciences of California, Inc.: Overall Financials, 2016-2018
  • Figure 14.62: Pacific Biosciences of California, Inc.: Revenue (by Product/Service), 2016-2018
  • Figure 14.63: Pacific Biosciences of California, Inc.: Revenue (by Region), 2016-2018
  • Figure 14.64: Pacific Biosciences of California, Inc.: R&D Expenditure, 2016-2018
  • Figure 14.65: Pacific Biosciences: SWOT Analysis
  • Figure 14.66: PerkinElmer: Product Offerings for the Global Tumor Genomics Market
  • Figure 14.67: Perkin Elmer: Overall Financials, 2017-2019
  • Figure 14.68: PerkinElmer: Revenue (by Products & Services), 2017-2019
  • Figure 14.69: PerkinElmer: Revenue (by Region), 2017-2019
  • Figure 14.70: PerkinElmer: R&D Expenditure, 2017-2019
  • Figure 14.71: PerkinElmer lnc.: SWOT Analysis
  • Figure 14.72: QIAGEN: Product Offerings for the Global Tumor Genomics Market
  • Figure 14.73: QIAGEN: Overall Financials, 2016-2018
  • Figure 14.74: QIAGEN: Revenue (by Business Model), 2016-2018
  • Figure 14.75: QIAGEN: Revenue (by Region), 2016-2018
  • Figure 14.76: QIAGEN: R&D Expenditure, 2016-2018
  • Figure 14.77: QIAGEN: SWOT Analysis
  • Figure 14.78: Siemens Healthineers AG: Product Offerings for the Global Tumor Genomics Market
  • Figure 14.79: Siemens Healthineers AG Overall Financials, 2017-2019
  • Figure 14.80: Siemens Healthineers AG: Revenue (by Product and Services), 2017-2019
  • Figure 14.81: Siemens Healthineers AG: Revenue (by Region), 2017-2019
  • Figure 14.82: Siemens Healthineers AG: R&D Expenditure, 2017-2019
  • Figure 14.83: Siemens Healthineers AG: SWOT Analysis
  • Figure 14.84: Thermo Fisher Scientific Inc.: Product Offerings for the Global Tumor Genomics Market
  • Figure 14.85: Thermo Fisher Scientific Inc.: Overall Financials, 2017-2019
  • Figure 14.86: Thermo Fisher Scientific Inc.: Net Revenue (by Business Segment), 2017-2019
  • Figure 14.87: Thermo Fisher Scientific Inc.: Net Revenue (by Region), 2017-2019
  • Figure 14.88: Thermo Fisher Scientific Inc.: R&D Expense, 2017-2019
  • Figure 14.89: Thermo Fisher Scientific, Inc.: SWOT Analysis